Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Gross Margin (2025)

Historic Gross Margin for ImmunityBio (IBRX) over the last 3 years, with Q3 2025 value amounting to 99.45%.

  • ImmunityBio's Gross Margin fell 5500.0% to 99.45% in Q3 2025 from the same period last year, while for Sep 2025 it was 99.55%, marking a year-over-year decrease of 4500.0%. This contributed to the annual value of 100.0% for FY2024, which is 0.0% changed from last year.
  • As of Q3 2025, ImmunityBio's Gross Margin stood at 99.45%, which was down 5500.0% from 99.49% recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Gross Margin ranged from a high of 100.0% in Q2 2023 and a low of 99.45% during Q3 2025
  • Moreover, its 3-year median value for Gross Margin was 100.0% (2023), whereas its average is 99.86%.
  • Per our database at Business Quant, ImmunityBio's Gross Margin changed by 0bps in 2024 and then tumbled by -5500bps in 2025.
  • ImmunityBio's Gross Margin (Quarter) stood at 100.0% in 2023, then changed by 0bps to 100.0% in 2024, then decreased by -1bps to 99.45% in 2025.
  • Its Gross Margin stands at 99.45% for Q3 2025, versus 99.49% for Q2 2025 and 99.65% for Q1 2025.